Projects
Statistical models in the evaluation of predictors of therapeutic success. Applications in Cancer and Covid-19 KU Leuven
Innovative research in recent years has led to the discovery of many promising targeted agents including immunotherapy such as monoclonal antibodies and vaccines. The varying mechanisms of action introduced by these novel agents challenge researchers to reconsider whether the conventional efficacy analyses adequately address the new mechanisms of action of these therapies [1]. There are two important aspect that need to be considered: 1) a ...
Non-covalent hapten-immunogen next generation anti-opioid nanovaccines Ghent University
The abusive use of opioid prescription drugs, often referred to as ‘the opioid crisis, has become a major global problem facing an exuberant number of deaths. To tackle this tremendous challenges, anti-opioid immunotherapy is considered as a promising therapy. The current generation of anti-opioid vaccines are based on random covalent conjugation of opioid haptens to a carrier protein in combination with an admixed adjuvant, and most likely ...
Mechanobiology control of immunogenic cell death by bio-polymers for cancer therapy Ghent University
Immunogene celdood (ICD) combineert het vermogen om zowel kankercellen te doden als tegelijkertijd anti-tumorimmuniteit te activeren, en impliceert ferroptose, wat een efficiënte antikankerstrategie representeert. Eén van de belangrijkste knelpunten voor ferroptose en andere ICD-modaliteiten is de effectieve inductie van opname van stervende kankercellen die ICD ondergaan door fagocyten. In ongepubliceerd onderzoek waarbij een nieuw en ...
Angiogenesis and Vascular Heterogeneity KU Leuven
Current anti-angiogenesis therapies (AATs) and traditional immunotherapy suffer resistance and insufficient efficacy in cancer treatment. To overcome these limitations, several characteristics of endothelial cells, such as their heterogeneity and function in immunity, will be studied for their importance in contributing to the partial failure of the above-mentioned therapies. By means of cutting-edge techniques, such as single-cell ...
Pathogenesis of EBV+ Lymphoproliferative disorders (LPDs) KU Leuven
EBV-positive diffuse large B-cell lymphoma, not otherwise specified (EBV+ DLBCL, NOS), is an aggressive B-cell lymphoma affecting mostly elderly patients, which results in death, when left untreated. This malignancy is an EBV-driven B-cell lymphoproliferative disorder occurring in patients with no identified underlying immunodeficiency. Primary treatment (R-CHOP) is not different from EBV-negative DLBCL, NOS, and gives an overall survival ...
Identification of novel anti-leukemic T cellreceptors for development of cell therapies using patient blood samples and cutting-edge computational modeling. University of Antwerp
Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment KU Leuven
Isocitrate dehydrogenase wildtype (IDHwt) glioblastoma (GBM) is the most frequent, aggressive and lethal brain tumour. It has a universally fatal prognosis with 85% of patients dying within two years. Effective precision medicine therapies are thus urgently required. This can only be achieved by focused multi-sectoral collaborations in innovative research disciplines. Overall, GLIORESOLVE will exploit the intractability of GBM to address ...
Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometry KU Leuven
Flow cytometry represents an essential technology in all
domains of fundamental, translational and clinical
biomedical research. At the KU Leuven, flow cytometric
services are centralized at the KU Leuven Flow and Mass
Cytometry core facility (KUL-FMC) and shaped by the needs
of its users. However, beyond life-time mid-range
cytometers threaten the research continuity. To warrant an
uninterrupted transition ...